-
EP3510048
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3510048
| EP3510048 - METHODS OF TREATING PD-L1 EXPRESSING CANCER [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 22.04.2020 Database last updated on 09.09.2024 | |
| Former | Request for examination was made Status updated on 14.06.2019 | ||
| Former | The international publication has been made Status updated on 23.03.2018 | ||
| Former | unknown Status updated on 29.09.2017 | Most recent event Tooltip | 27.09.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Mayo Foundation for Medical Education and Research 200 First Street S.W. Rochester, Minnesota 55905 / US | [2019/29] | Inventor(s) | 01 /
MARKOVIC, Svetomir N. c/o Mayo Foundation for Medical Education and Research 200 First Street SW Rochester, Minnesota 55905 / US | 02 /
NEVALA, Wendy K. c/o Mayo Foundation for Medical Education and Research 200 First Street SW Rochester, Minnesota 55905 / US | [2019/29] | Representative(s) | Script Intellectual Property LLP Suite J, Anchor House School Close Chandlers Ford Eastleigh, Hampshire SO53 4DY / GB | [N/P] |
| Former [2019/29] | Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB | Application number, filing date | 17768911.4 | 05.09.2017 | [2019/29] | WO2017US50137 | Priority number, date | US201662383938P | 06.09.2016 Original published format: US 201662383938 P | [2019/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018048816 | Date: | 15.03.2018 | Language: | EN | [2018/11] | Type: | A1 Application with search report | No.: | EP3510048 | Date: | 17.07.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 15.03.2018 takes the place of the publication of the European patent application. | [2019/29] | Search report(s) | International search report - published on: | EP | 15.03.2018 | Classification | IPC: | C07K16/28, A61K9/00, A61K47/69, A61P35/00, A61K39/395, A61K31/337 | [2019/29] | CPC: |
C07K16/2827 (EP,KR,US);
A61K47/6929 (EP,KR,US);
A61K31/337 (EP,KR,US);
A61K31/555 (EP);
A61K39/3955 (EP);
A61K39/39558 (KR);
A61K45/06 (EP,KR,US);
A61K47/643 (EP,KR);
A61K47/6849 (EP);
A61K47/6851 (KR);
A61P35/00 (EP,KR,US);
C07K14/76 (US);
A61K2039/505 (KR);
A61K2039/545 (KR);
A61K2039/6031 (EP,KR);
| C-Set: |
A61K31/337, A61K2300/00 (EP);
A61K31/555, A61K2300/00 (EP);
A61K39/3955, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/29] | Title | German: | VERFAHREN ZUR BEHANDLUNG VON PD-L1-EXPRIMIERENDEM KREBS | [2019/29] | English: | METHODS OF TREATING PD-L1 EXPRESSING CANCER | [2019/29] | French: | PROCÉDÉS DE TRAITEMENT DU CANCER EXPRIMANT PD-L1 | [2019/29] | Entry into regional phase | 19.03.2019 | National basic fee paid | 19.03.2019 | Designation fee(s) paid | 19.03.2019 | Examination fee paid | Examination procedure | 19.03.2019 | Examination requested [2019/29] | 19.03.2019 | Date on which the examining division has become responsible | 28.11.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 05.02.2020 | Amendment by applicant (claims and/or description) | 28.04.2020 | Despatch of a communication from the examining division (Time limit: M04) | 04.09.2020 | Reply to a communication from the examining division | 07.12.2020 | Despatch of a communication from the examining division (Time limit: M06) | 09.06.2021 | Reply to a communication from the examining division | 19.01.2023 | Despatch of a communication from the examining division (Time limit: M04) | 22.05.2023 | Reply to a communication from the examining division | Request for further processing for: | 05.02.2020 | Request for further processing filed | 05.02.2020 | Full payment received (date of receipt of payment) Request granted | 13.02.2020 | Decision despatched | Fees paid | Renewal fee | 27.09.2019 | Renewal fee patent year 03 | 28.09.2020 | Renewal fee patent year 04 | 27.09.2021 | Renewal fee patent year 05 | 27.09.2022 | Renewal fee patent year 06 | 27.09.2023 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2012154861 (MAYO FOUNDATION [US], et al) [A] 1-68* examples 1-8; claims 1-12 *; | [I]WO2015048520 (GENENTECH INC [US], et al) [I] 1-68 * claims 1-12 *; | [A]WO2015195476 (MAYO FOUNDATION [US]) [A] 1-68 * example 2; claims 1-11 *; | [XI]WO2016089873 (CELGENE CORP [US]) [X] 25-27 * paragraph [0211] - paragraph [0213]; figures 1-3; examples 10-12; claims 1-119 * [I] 1-68; | [I] - SYLVIA ADAMS ET AL, "Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC)", vol. 34, no. 5, doi:10.1200/JCO.2016.34.15_suppl.1009, (201605), JOURNAL OF CLINICAL ONCOLOGY, URL: http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.1009, (20171108), XP055422710 [I] 1-68 * the whole document * DOI: http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.1009 | [I] - Anonymous, "Atezolizumab Plus Abraxane Promising New Treatment for Triple-Negative Breast Cancer", (20160107), pages 1 - 2, UNM Comprehensive Cancer Center, URL: http://cancer.unm.edu/2016/01/07/atezolizumab-plus-abraxane-promising-new-treatment-for-triple-negative-breast-cancer/, (20171020), XP055417747 [I] 1-68 * the whole document * | [I] - Silas Inman, "OT1-01-06 Atezolizumab/Nab-Paclitaxel Combo Shows High Response Rates in TNBC", INTERNET CITATION, (20151210), OneLive, URL: http://www.onclive.com/conference-coverage/sabcs-2015/atezolizumab-nab-paclitaxel-combo-shows-high-response-rates-in-tnbc, (20171020), XP002775312 [I] 1-68 * the whole document * | [I] - Emens L, et al., "OT1-01-06 A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients withmetastatic triple-negative breast cancer (mTNBC)", INTERNET CITATION, (20160501), 2015 San Antonio Breast Cancer Symposium, URL: https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2015-Abstracts.pdf?v=5, (20171106), XP002775313 [I] 1-68 * the whole document * | [I] - Adams S, et al., "Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatictriple-negative breast cancer", INTERNET CITATION, (20160215), 2015 San Antonio Breast Cancer Symposium, URL: https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2015-Abstracts.pdf?v=5, (20171115), XP002775314 [I] 1-68 * the whole document * | [I] - Anonymous, "A Phase III, Multicenter, Randomized Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab Paclitaxel Compared With Placebo With Nab Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer", (20150421), ClinicalTrials.gov, URL: https://clinicaltrials.gov/archive/NCT02425891/2016_09_01, (20171020), XP055417752 [I] 1-68 * the whole document * | by applicant | WO2014055415 | WO2016057554 | - ISHIDA et al., EMBO J., (19920000), vol. 11, page 3887 | - PHILIPS; ATKINS, "Therapeutic uses of anti-PD-1 and anti-PD-Ll antibodies", International Immunology, vol. 27, no. 1, doi:doi:10.1093/intimm/dxu095, pages 39 - 46, XP055217958 DOI: http://dx.doi.org/10.1093/intimm/dxu095 | - LUSSIER et al., J. Immunotherapy of Cancer, (20150000), vol. 3, page 21 | - KOYAMA et al., Nature Communications, (20160217), vol. 7, pages 1 - 9 | - LANZAVECCHIA et al., Eur. J. Immunol., (19870000), vol. 17, page 105 | - HUSTON et al., Proc. Natl. Acad. Sci. U.S.A., (19880000), vol. 85, pages 5879 - 5883 | - BIRD et al., Science, (19880000), vol. 242, pages 423 - 426 | - Hunkapiller and Hood, Nature, vol. 323, pages 15 - 16 | WO2015US54295 | WO2017US45643 |